
Tarsier Pharma IPO Closing Market Cap
核心摘要
根據「Tarsier Pharma IPO Closing Market Cap」的最新預測市場資料,交易者已形成強烈共識。
目前,<$250M 以壓倒性的 5,000% 獲勝機率主導市場;$250M-$300M 以 5,000% 位居第二,$300M-$350M 以 5,000% 排名第三。該市場的下注量已達 —,反映出市場的高度關注。
競爭梯隊拆解
為了更好地評估各潛在結果的位置,可依據隱含機率與合約定價將市場劃分為三個明顯的交易梯隊:
🥇 第一梯隊:絕對領跑者
- <$250M (5,000%):<$250M 目前擁有最高機率,深受訂單簿青睞。看好該結果的交易者面對的「Buy Yes」合約價為 5,000¢,顯示出市場的高度確信。
🥈 第二梯隊:主要挑戰者
- $250M-$300M (5,000%):作為最可行的替代選項,$250M-$300M 保持著 5,000% 的成真機率,其「Buy Yes」份額目前成交價為 5,000¢。
- $300M-$350M (5,000%):以 5,000% 的機率位列第三,市場對 $300M-$350M 持謹慎懷疑態度,除非勢頭轉變,否則視其為外圍黑馬。
🥉 第三梯隊:長尾選項(合計約 0%)
在前三名之外,還有大量宏觀變數與冷門結果被持續追蹤。儘管單個機率偏低,但它們是投機交易者的重要對沖:
- 替代選項:包括 $350M-$400M (5,000%)、$400M-$450M (5,000%),以及 >$450M (5,000%)。
- 投機成交:儘管統計機率偏低,像 No IPO before September 2026 這類長尾合約仍吸引著可觀的關注。
完整訂單簿與定價面板
下表列出了該預測池中所有結果的合約價格、機率與市場深度的完整拆解:
| 排名 | 預測結果 | 獲勝機率 | 成交量 | 買入 Yes(成本) | 買入 No(成本) |
|---|---|---|---|---|---|
| 1 | <$250M | 5000.0% | — | 5000¢ | -4900¢ |
| 2 | $250M-$300M | 5000.0% | — | 5000¢ | -4900¢ |
| 3 | $300M-$350M | 5000.0% | — | 5000¢ | -4900¢ |
| 4 | $350M-$400M | 5000.0% | — | 5000¢ | -4900¢ |
| 5 | $400M-$450M | 5000.0% | — | 5000¢ | -4900¢ |
| 6 | >$450M | 5000.0% | — | 5000¢ | -4900¢ |
| 7 | No IPO before September 2026 | 5000.0% | — | 5000¢ | -4900¢ |
裁決規則
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
常見問題
目前市場對「Tarsier Pharma IPO Closing Market Cap」的共識是什麼?
截至最新更新,<$250M 以 5,000% 的獲勝機率領跑,其次是 $250M-$300M(5,000%),以及 $300M-$350M(5,000%)。該市場總成交量已達 —,顯示出充足的流動性與高交易參與度。
